Keyphrases
2-year Follow-up
14%
Adalimumab
20%
Angiogenesis
13%
Ankylosing Spondylitis Disease Activity Score (ASDAS)
20%
Axial Spondyloarthritis (AxSpA)
45%
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
26%
Biologic DMARDs
27%
Bone Erosion
10%
Bone Turnover
18%
C-reactive Protein
21%
Cartilage Turnover
18%
Clinical Outcomes
14%
Clinical Practice
38%
Clinical Practice Guidelines
10%
Clinical Remission
38%
Clinical Response
13%
DANBIO Registry
45%
Disease Activity
23%
Disease Activity Score
9%
Disease Activity Score 28 (DAS28)
12%
Drug Survival
27%
Etanercept
10%
Global Rankings
16%
Glucocorticoid Therapy
13%
Incidence Rate
10%
Inflammation
27%
Inflammatory Biomarkers
18%
Infliximab
19%
Inhibitor Therapy
18%
Inhibitor Treatment
15%
Magnetic Resonance Imaging
34%
Methotrexate
13%
Odds Ratio
11%
Outpatient Clinic
12%
Outpatient Follow-up
9%
Prednisolone
11%
Radiographic Progression
36%
Radiography
10%
Remission
14%
Rheumatoid Arthritis
100%
Rheumatoid Arthritis Patients
43%
Rheumatologists
14%
Routine Care
43%
Scoring System
10%
Synovitis
9%
TNF Inhibitors
13%
Treatment Drugs
11%
Treatment Response
31%
Tumour Necrosis Factor Inhibitor (TNFi)
68%
Ultrasound
14%
Medicine and Dentistry
Adalimumab
11%
Aggrecan
9%
Angiogenesis
13%
Ankylosing Spondylitis
9%
Ankylosing Spondylitis Disease Activity Score
11%
BASDAI
22%
Biological Marker
27%
Bone Erosion
10%
Bone Turnover
18%
C Reactive Protein
19%
Carboxy Terminal Sequence
13%
Cardiovascular Agent
9%
Cartilage Oligomeric Matrix Protein
9%
Cohort Analysis
11%
Collagen Type 2
9%
Computed Radiography
9%
Computer Assisted Tomography
9%
Cross-Link
13%
DAS28
6%
Diagnosis
9%
Digoxin
9%
Disease Activity
10%
Disease Activity Score
9%
Drug Dose Regimen
9%
Drug Response
9%
Echography
27%
Fluorodeoxyglucose
9%
Fragility Fracture
9%
Furosemide
9%
Glucocorticoid
9%
Infliximab
10%
Interleukin 6
9%
Magnetic Resonance Imaging
43%
Osteocalcin
9%
Outpatient
12%
Patient-Reported Outcome
9%
Polymyalgia Rheumatica
9%
Positron Emission Tomography
9%
Psoriatic Arthritis
9%
Randomized Controlled Trial
9%
Rheumatoid Arthritis
63%
Scoring System
9%
Spondylarthritis
27%
Stromelysin
9%
Telopeptide
13%
Thiazide Diuretic Agent
9%
TNF Inhibitor
47%
Treatment Response
22%
Tumor Necrosis Factor
7%
Vasculotropin
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
20%
Adrenal Insufficiency
9%
Arthritis
5%
Biological Marker
9%
C Reactive Protein
9%
Cardiovascular Agent
9%
Cohort Study
14%
Comorbidity
9%
Digoxin
9%
Disease
18%
Disease Activity
7%
Disease Activity Score
15%
Etanercept
10%
Fluorodeoxyglucose
9%
Fragility Fracture
9%
Furosemide
9%
Glucocorticoid
14%
Immunoglobulin M
9%
Inflammation
28%
Infliximab
19%
Mannan Binding Lectin
9%
Methotrexate
13%
Mouse Model
9%
Prednisolone
12%
Proximal Humerus Fracture
7%
Psoriatic Arthritis
9%
Remission
28%
Rheumatic Polymyalgia
9%
Rheumatoid Arthritis
72%
Serine Proteinase
9%
Spondylarthritis
9%
Thiazide Diuretic Agent
9%
Tumor Necrosis Factor
7%
Tumor Necrosis Factor Inhibitor
42%
